FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry. Described monoclonal humanised antibody, which specifically binds with extracellular domain of receptor tyrosine kinase AXL and which, at least, partly inhibits AXL activity. Claimed is nucleic acid molecule, coding described antibody. Claimed is nucleic acid molecule, coding said antibody. Also claimed is expression vector and host cell. Disclosed is method of said antibody production. Also disclosed is pharmaceutical composition, which contains described antibody. Described is method for diagnostics of health condition, associated with AXL expression. Disclosed is application of described antibody for treating drug-resistant cancer.
EFFECT: invention extends arsenal of medications, in particular, applied for cancer therapy.
17 cl, 39 dwg, 2 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Siglec-15 ANTIBODY | 2010 |
|
RU2539790C2 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2644678C1 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2590711C2 |
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| ANTIBODY TO EPHA2 | 2008 |
|
RU2525133C2 |
| HUMANISED ANTIBODIES TO CDCP1 | 2010 |
|
RU2571207C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| MONOCLONAL ANTIBODY ABLE TO BIND TO SPECIFIC DISCONTINUOUS EPITOPE PLACED IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ITS ANTIGEN-BINDING FRAGMENT | 2010 |
|
RU2542472C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
